Senators urge CMS not to restrict coverage of Biogen Alzheimer's drug Aduhelm

Win McNamee/Getty Images News

• Sens. Susan Collins (R-Maine) and Shelley Moore Capito (R-W.V.) are asking the Centers for Medicare and Medicaid Services ("CMS") to not restrict patient access to Biogen's (BIIB +1.9%) Alzheimer's treatment Aduhelm (aducanumab).
• In January, CMS issued a draft National Coverage Determination to limit coverage of the treatment only for those currently enrolled in clinical trials.
• In a letter to CMS Administrator Chiquita Brooks-LaSure, the senators argue that the agency should consider stakeholder feedback as the final decision could impact further developments for Alzheimer's treatments.
• They also cited the U.S. FDA's approval of the drug which had a "meaningful effect on the reduction of beta amyloid plaque, which is expected, although not established, to predict a clinical benefit."
• In late January, an examination of comments received by CMS on the draft coverage decision found that the vast majority agreed with the agency to limit coverage. The comment deadline was Feb. 10.
• CMS is expected to make a final coverage determination in April.
• Read why Seeking Alpha contributor Bret Jensen considers Biogen a hold.

Comments

[Heather82]

Pretty sure Medicare won’t listen to them also by chance if Medicare approved It no doctors will prescribe it . It’s a dead meat now

[smikhail]

Politicians opining on the efficacy of a drug's merit is asinine. Call me cynical, but I would not be shocked if the basis of their concern is they are long BIIB.

[brad_scat]

@smikhail no doubt. They are clueless, and are only concerned about their own pockets. I’d be surprised if that wasn’t the case.

[RJSP]

Hmmm I wonder who pays Jonathon Block? What a mystery this is.